Valuation Abbott Laboratories Bulgaria S.E.
Stocks
ABL
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.51 EUR | +16.78% |
|
0.00% | -30.19% |
| 01:32pm | Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise | MT |
| 12:11pm | S&P 500, Nasdaq fall as chips extend losses; earnings and data in focus | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 155,492 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -28.63% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 163,560 | 160,947 | 157,071 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -26.41% | -1.6% | -2.41% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 22.3x | 19.1x | 16.4x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.14x | 3.01x | 2.81x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | 3x | 1.1x | 1x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.09x | 2.84x | 2.65x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.25x | 2.94x | 2.68x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 12.1x | 11x | 9.86x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 14x | 12.4x | 11x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 18.9x | 17.1x | 15.1x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 5.3% | 5.86% | 6.61% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.549 | 2.718 | 2.858 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.86% | 3.05% | 3.2% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.997 | 4.681 | 5.438 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 63.8% | 58.1% | 52.6% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,262 | 54,740 | 58,591 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,500 | 14,687 | 15,938 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,661 | 13,022 | 14,302 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,923 | 8,285 | 9,226 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 8,068 | 5,455 | 1,580 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 89.27 | 89.27 | 89.27 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,741,813 | - | - |
| Announcement Date | 1/26/22 | 1/25/23 | 1/24/24 | 1/22/25 | 1/22/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 18.26x | 3.22x | 11.31x | 3.69% | 103B | ||
| 16.5x | 0.18x | 11.68x | 0.8% | 57.7B | ||
| 31.96x | 7.77x | 20.31x | 1.25% | 52.27B | ||
| 38.59x | 3.08x | 10.51x | 2.49% | 42.68B | ||
| 37.81x | 1.38x | 12.14x | 0.26% | 33.35B | ||
| 29.71x | 5.26x | 16.78x | -.--% | 28.06B | ||
| 42.66x | 7.46x | 26.92x | 0.24% | 25.36B | ||
| 48.05x | 6.45x | 20.7x | 0.45% | 21.03B | ||
| 23.26x | 3.41x | 12.24x | 1.25% | 20.61B | ||
| Average | 31.87x | 4.24x | 15.84x | 1.16% | 42.67B | |
| Weighted average by Cap. | 28.16x | 3.82x | 14.57x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
















